Paul Gonter
Medical Oncology · Venice, FLNPI 1295726933
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,004 and has fallen 98.1% since, to $38 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 238 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$611
- Genentech USA, Inc.$480
- Merck$454
- E.r. Squibb & Sons, L.L.C.$421
- Lilly USA, LLC$296
- Bristol Myers Squibb$294
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,391100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $611 |
| Genentech USA, Inc. | 27 | $480 |
| Merck | 29 | $454 |
| E.r. Squibb & Sons, L.L.C. | 30 | $421 |
| Lilly USA, LLC | 11 | $296 |
| Bristol Myers Squibb | 19 | $294 |
| Novartis | 17 | $248 |
| Johnson & Johnson | 12 | $187 |
| Pfizer | 9 | $135 |
| Sanofi | 3 | $124 |
| AbbVie | 7 | $123 |
| Seagen Inc. | 7 | $114 |
| Amgen | 7 | $108 |
| Astellas Pharma US Inc | 5 | $78 |
| Gilead(2 entities) | 4 | $70 |
| Incyte Corporation | 4 | $65 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Puma Biotechnology, Inc. | 3 | $51 |
| Exelixis Inc. | 4 | $49 |
| Myovant Sciences Inc. | 3 | $49 |
| Rigel Pharmaceuticals, Inc. | 3 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $43 |
| Bayer | 2 | $32 |
| Tersera Therapeutics LLC | 2 | $29 |
| Innate Pharma, Inc | 1 | $24 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
| Epizyme, Inc. | 1 | $23 |
| Partner Therapeutics, Inc. | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Blueprint Medicines Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,408 in reported general payments places this provider in the 35th percentile of 507 medical oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $6,693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $611 | $6,69312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Venice
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.